These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 8052965)
1. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. Brister SJ; Ofosu FA; Heigenhauser GJ; Gianese F; Buchanan MR Thromb Haemost; 1994 Apr; 71(4):468-73. PubMed ID: 8052965 [TBL] [Abstract][Full Text] [Related]
2. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Brister SJ; Ofosu FA; Buchanan MR Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131 [TBL] [Abstract][Full Text] [Related]
3. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389 [TBL] [Abstract][Full Text] [Related]
4. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247 [TBL] [Abstract][Full Text] [Related]
6. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. Despotis GJ; Joist JH J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245 [TBL] [Abstract][Full Text] [Related]
7. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038 [TBL] [Abstract][Full Text] [Related]
8. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195 [TBL] [Abstract][Full Text] [Related]
9. The haemorrhagic and antithrombotic effects of dermatan sulphate. Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass. Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162 [TBL] [Abstract][Full Text] [Related]
11. [Dermatan sulfate and the prevention of experimental venous thrombosis]. Desnoyers P; Bara L; Samama M Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877 [TBL] [Abstract][Full Text] [Related]
12. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Chan AK; Leaker M; Burrows FA; Williams WG; Gruenwald CE; Whyte L; Adams M; Brooker LA; Adams H; Mitchell L; Andrew M Thromb Haemost; 1997 Feb; 77(2):270-7. PubMed ID: 9157580 [TBL] [Abstract][Full Text] [Related]
13. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093 [TBL] [Abstract][Full Text] [Related]
14. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding. Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710 [TBL] [Abstract][Full Text] [Related]
15. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin. Thomas DP; Gray E; Merton RE Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536 [TBL] [Abstract][Full Text] [Related]
17. Low affinity heparin is an antithrombotic agent. Gray E; Cesmeli S; Lormeau JC; Davies AB; Lane DA Thromb Haemost; 1994 Feb; 71(2):203-7. PubMed ID: 8191399 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. Bel A; Borik W; Davidson S; Helies JM; Stimmer L; Fremes S; Zelenkofske S; Rusconi C; Alexander J; Alexander D; Menasché P; Pepper J Eur J Cardiothorac Surg; 2016 Feb; 49(2):682-9. PubMed ID: 25953802 [TBL] [Abstract][Full Text] [Related]
19. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293 [TBL] [Abstract][Full Text] [Related]
20. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit. Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]